Katrina A. Bicknell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Katrina A. Bicknell has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Gavin Brooks
School of Biological Sciences; University of Reading; Whiteknights Reading United Kingdom
7 shared publications- Gavin Brooks
School of Biological Sciences, University of Reading, Reading, United Kingdom
7 shared publications Carmen H. Coxon
School of Pharmacy, University of Reading, Reading, United Kingdom
4 shared publicationsFleur L. Moseley
School of Pharmacy, University of Reading, Whiteknights, Reading, Berkshire, UK
3 shared publications- Julian Alexander Hiscox
Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool
3 shared publications Abeer Dannoura
School of Pharmacy & ICMR, University of Reading, UK
2 shared publications
Latest Publications
- 30 October 2015
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 78  (11) , 2598-2608
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids
Epidemiological studies suggest that fruits and vegetables may play a role in promoting bone growth and preventing age-related bone loss, attributable, at least in part, to phytochemicals such as flavonoids stimulating osteoblastogenesis. Through systematically screening the effect of flavonoids on the osteogenic differentiation of human mesenchymal stem cells in vitro and correlating activity with chemical structure using comparative molecular field analysis, we have successfully identified important structural features that relate to their activity, as well as reliably predicted the activity of compounds with unknown activity. Contour maps emphasized the importance of electronegativity, steric bulk, and a 2-Câ3-C double bond at the flavonoid C-ring, as well as overall electropositivity and reduced steric bulk at the flavonoid B-ring. These results support a role for certain flavonoids in promoting osteogenic differentiation, thus their potential for preventing skeletal deterioration, as well as providin...
- 30 October 2015
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 78  (11) , 2598-2608
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids
Epidemiological studies suggest that fruits and vegetables may play a role in promoting bone growth and preventing age-related bone loss, attributable, at least in part, to phytochemicals such as flavonoids stimulating osteoblastogenesis. Through systematically screening the effect of flavonoids on the osteogenic differentiation of human mesenchymal stem cells in vitro and correlating activity with chemical structure using comparative molecular field analysis, we have successfully identified important structural features that relate to their activity, as well as reliably predicted the activity of compounds with unknown activity. Contour maps emphasized the importance of electronegativity, steric bulk, and a 2-Câ3-C double bond at the flavonoid C-ring, as well as overall electropositivity and reduced steric bulk at the flavonoid B-ring. These results support a role for certain flavonoids in promoting osteogenic differentiation, thus their potential for preventing skeletal deterioration, as well as providin...
TROGLITAZONE INHIBITS VASCULAR SMOOTH MUSCLE CELL PROLIFERATION IN A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPARÎł)-INDEPENDENT MANNER
Re-occlusion of blood vessels following percutaneous coronary intervention with stenting (in stent stenosis) occurs in 5â10% of patients receiving drug-eluting stents. Re-occlusion of the treated vessel is observed when vascular smooth muscle cells (VSMCs) proliferate and migrate in response to vessel injury, inflammation and impaired healing of the endothelial cell layer. Novel drug eluting stents that reduce inflammation and permit endothelial repair whilst preventing detrimental VSMC proliferation and migration might reduce the occurrence of in stent restenosis. We previously have shown that ibuprofen has differential effects on vascular smooth muscle and endothelial cell proliferation and migration and, thus, might be a promising drug to deliver in a novel drug eluting stent platform. We do not fully understand why vascular smooth muscle and endothelial cells respond differently to ibuprofen but hypothesise that ibuprofen is regulating VSM C proliferation and migration, at least in part, via a peroxisome proliferator-activated receptor gamma (PPARÎł)-dependent mechanism. In this study, we have used PPARÎł agonists, troglitazone, pioglitazone, and rosiglitazone, to establish the role of PPARÎł in the regulation of cell proliferation in the A10 VSMC cell line. Interestingly, whilst 50 ÂľM and 100 ÂľM troglitazone inhibited A10 VSMC proliferation by 58.9Âą4.6% and 21.6Âą4.8%, respectively, pioglitazone and rosiglitazone had no effect on VSMC cell proliferation at any concentrations tested. The observations that only one PPARÎł agonist tested inhibited VSMC proliferation and that high concentrations of troglitazone were required to observe a significant effect (EC50=54.6 ÂľM) suggest that troglitazone might be acting in a PPARÎł-independent manner.
TROGLITAZONE INHIBITS VASCULAR SMOOTH MUSCLE CELL PROLIFERATION IN A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPARÎł)-INDEPENDENT MANNER
Re-occlusion of blood vessels following percutaneous coronary intervention with stenting (in stent stenosis) occurs in 5â10% of patients receiving drug-eluting stents. Re-occlusion of the treated vessel is observed when vascular smooth muscle cells (VSMCs) proliferate and migrate in response to vessel injury, inflammation and impaired healing of the endothelial cell layer. Novel drug eluting stents that reduce inflammation and permit endothelial repair whilst preventing detrimental VSMC proliferation and migration might reduce the occurrence of in stent restenosis. We previously have shown that ibuprofen has differential effects on vascular smooth muscle and endothelial cell proliferation and migration and, thus, might be a promising drug to deliver in a novel drug eluting stent platform. We do not fully understand why vascular smooth muscle and endothelial cells respond differently to ibuprofen but hypothesise that ibuprofen is regulating VSM C proliferation and migration, at least in part, via a peroxisome proliferator-activated receptor gamma (PPARÎł)-dependent mechanism. In this study, we have used PPARÎł agonists, troglitazone, pioglitazone, and rosiglitazone, to establish the role of PPARÎł in the regulation of cell proliferation in the A10 VSMC cell line. Interestingly, whilst 50 ÂľM and 100 ÂľM troglitazone inhibited A10 VSMC proliferation by 58.9Âą4.6% and 21.6Âą4.8%, respectively, pioglitazone and rosiglitazone had no effect on VSMC cell proliferation at any concentrations tested. The observations that only one PPARÎł agonist tested inhibited VSMC proliferation and that high concentrations of troglitazone were required to observe a significant effect (EC50=54.6 ÂľM) suggest that troglitazone might be acting in a PPARÎł-independent manner.
- 1 June 2014
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 66  (6) , 779-792
Ibuprofen inhibits migration and proliferation of human coronary artery smooth muscle cells by inducing a differentiated phenotype: role of peroxisome proliferator-activated receptor Îł
Objectives: The search for agents that are capable of preventing restenosis and reduce the risk of late thrombosis is of utmost importance. In this study we aim to evaluate the in vitro effects of ibuprofen on proliferation and migration of human coronary artery smooth muscle cells and on endothelial cells. Methods: Cell proliferation was evaluated by trypan blue exclusion. Cell migration was assessed by wound-healing âscratchâ assay and time-lapse video microscopy. Protein expression was assessed by immunoblotting, and morphology by immunocytochemistry. The involvement of the PPARÎł pathway was studied with the agonist troglitazone, and the use of selective antagonists such as PGF2Îą and GW9662. Key findings: We demonstrate that ibuprofen inhibits proliferation and migration of HCASMCs and induces a switch in HCASMCs towards a differentiated and contractile phenotype, and that these effects are mediated through the PPARÎł pathway. Importantly we also show that the effects of ibuprofen are cell type-specific as it does not affect migration and proliferation of endothelial cells. Conclusions: Taken together, our results suggest that ibuprofen could be an effective drug for the development of novel drug-eluting stents that could lead to reduced rates of restenosis and potentially other complications of DES implantation.
- 1 June 2014
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 66  (6) , 779-792
Ibuprofen inhibits migration and proliferation of human coronary artery smooth muscle cells by inducing a differentiated phenotype: role of peroxisome proliferator-activated receptor Îł
Objectives: The search for agents that are capable of preventing restenosis and reduce the risk of late thrombosis is of utmost importance. In this study we aim to evaluate the in vitro effects of ibuprofen on proliferation and migration of human coronary artery smooth muscle cells and on endothelial cells. Methods: Cell proliferation was evaluated by trypan blue exclusion. Cell migration was assessed by wound-healing âscratchâ assay and time-lapse video microscopy. Protein expression was assessed by immunoblotting, and morphology by immunocytochemistry. The involvement of the PPARÎł pathway was studied with the agonist troglitazone, and the use of selective antagonists such as PGF2Îą and GW9662. Key findings: We demonstrate that ibuprofen inhibits proliferation and migration of HCASMCs and induces a switch in HCASMCs towards a differentiated and contractile phenotype, and that these effects are mediated through the PPARÎł pathway. Importantly we also show that the effects of ibuprofen are cell type-specific as it does not affect migration and proliferation of endothelial cells. Conclusions: Taken together, our results suggest that ibuprofen could be an effective drug for the development of novel drug-eluting stents that could lead to reduced rates of restenosis and potentially other complications of DES implantation.
- 10 June 2013
- Published by Wiley in Macromolecular Bioscience
- Vol. 13  (9) , 1163-1173
A Comparison of Thiolated and Disulfide-Crosslinked Polyethylenimine for Nonviral Gene Delivery
Branched polyethylenimine (25 kDa) is thiolated and compared with redoxâsensitive crosslinked derivatives. Both polymers thiol contents are assessed; the thiolated polymers have 390â2300 mmol SH groups/mol, whereas the crosslinked polymers have lower thiol contents. Cytotoxicity assays show that both modified polymers give lower hemolysis than unmodified PEI. Increased thiol content increases gene transfer efficiency but also elevates cytotoxicity. Crosslinking improves plasmid DNA condensation and enhances transfection efficiency, but extensive crosslinking overstabilizes the polyplexes and decreases transfection, emphasizing the need to balance polyplex stabilization and unpacking. Thus, at low levels of crosslinking, 25 kDa PEI can be an efficient redoxâsensitive carrier system.
- 10 June 2013
- Published by Wiley in Macromolecular Bioscience
- Vol. 13  (9) , 1163-1173
A Comparison of Thiolated and Disulfide-Crosslinked Polyethylenimine for Nonviral Gene Delivery
Branched polyethylenimine (25 kDa) is thiolated and compared with redoxâsensitive crosslinked derivatives. Both polymers thiol contents are assessed; the thiolated polymers have 390â2300 mmol SH groups/mol, whereas the crosslinked polymers have lower thiol contents. Cytotoxicity assays show that both modified polymers give lower hemolysis than unmodified PEI. Increased thiol content increases gene transfer efficiency but also elevates cytotoxicity. Crosslinking improves plasmid DNA condensation and enhances transfection efficiency, but extensive crosslinking overstabilizes the polyplexes and decreases transfection, emphasizing the need to balance polyplex stabilization and unpacking. Thus, at low levels of crosslinking, 25 kDa PEI can be an efficient redoxâsensitive carrier system.
- 1 May 2011
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 63  (5) , 648-656
Limitations of the MRL mouse as a model for cardiac regeneration
Objective: Myocardial repair following injury in mammals is restricted such that damaged areas are replaced by scar tissue, impairing cardiac function. MRL mice exhibit exceptional regenerative healing in an ear punch wound model. Some myocardial repair with restoration of heart function has also been reported following cryoinjury. Increased cardiomyocyte proliferation and a foetal liver stem cell population were implicated. We investigated molecular mechanisms facilitating myocardial repair in MRL mice to identify potential therapeutic targets in non-regenerative species. Methods: Expressions of specific cell-cycle regulators that might account for regeneration (CDKs 1, 2, 4 and 6; cyclins A, E, D1 and B1; p21, p27 and E2F5) were compared by immunoblotting in MRL and control C57BL/6 ventricles during development. Flow cytometry was used to investigate stem cell populations in livers from foetal mice, and infarct sizes were compared in coronary artery-ligated and sham-treated MRL and C57BL/6 adult mice. Key findings: No differences in the expressions of cell cycle regulators were observed between the two strains. Expressions of CD34+Sca1+ckit-, CD34+Sca1+ckit+ and CD34+Sca1-ckit+ increased in livers from C57BL/6 vs MRL mice. No differences were observed in infarct sizes, levels of fibrosis, Ki67 staining or cardiac function between MRL and C57BL/6 mice. Conclusions: No intrinsic differences were observed in cell cycle control molecules or stem cell populations between MRL and control C57BL mouse hearts. Pathophysiologically relevant ischaemic injury is not repaired more efficiently in MRL myocardium, questioning the use of the MRL mouse as a reliable model for cardiac regeneration in response to pathophysiologically relevant forms of injury.
- 1 May 2011
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 63  (5) , 648-656
Limitations of the MRL mouse as a model for cardiac regeneration
Objective: Myocardial repair following injury in mammals is restricted such that damaged areas are replaced by scar tissue, impairing cardiac function. MRL mice exhibit exceptional regenerative healing in an ear punch wound model. Some myocardial repair with restoration of heart function has also been reported following cryoinjury. Increased cardiomyocyte proliferation and a foetal liver stem cell population were implicated. We investigated molecular mechanisms facilitating myocardial repair in MRL mice to identify potential therapeutic targets in non-regenerative species. Methods: Expressions of specific cell-cycle regulators that might account for regeneration (CDKs 1, 2, 4 and 6; cyclins A, E, D1 and B1; p21, p27 and E2F5) were compared by immunoblotting in MRL and control C57BL/6 ventricles during development. Flow cytometry was used to investigate stem cell populations in livers from foetal mice, and infarct sizes were compared in coronary artery-ligated and sham-treated MRL and C57BL/6 adult mice. Key findings: No differences in the expressions of cell cycle regulators were observed between the two strains. Expressions of CD34+Sca1+ckit-, CD34+Sca1+ckit+ and CD34+Sca1-ckit+ increased in livers from C57BL/6 vs MRL mice. No differences were observed in infarct sizes, levels of fibrosis, Ki67 staining or cardiac function between MRL and C57BL/6 mice. Conclusions: No intrinsic differences were observed in cell cycle control molecules or stem cell populations between MRL and control C57BL mouse hearts. Pathophysiologically relevant ischaemic injury is not repaired more efficiently in MRL myocardium, questioning the use of the MRL mouse as a reliable model for cardiac regeneration in response to pathophysiologically relevant forms of injury.
- Open Access
- 25 August 2009
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 4  (8) , e6752
Over Expression of Plk1 Does Not Induce Cell Division in Rat Cardiac Myocytes In Vitro
Mammalian cardiac myocytes withdraw from the cell cycle during post-natal development, resulting in a non-proliferating, fully differentiated adult phenotype that is unable to repair damage to the myocardium, such as occurs following a myocardial infarction. We and others previously have shown that forced expression of certain cell cycle molecules in adult cardiac myocytes can promote cell cycle progression and division in these cells. The mitotic serine/threonine kinase, Polo-like kinase-1 (Plk1), is known to phosphorylate and activate a number of mitotic targets, including Cdc2/Cyclin B1, and to promote cell division. The mammalian Plk family are all differentially regulated during the development of rat cardiac myocytes, with Plk1 showing the most dramatic decrease in both mRNA, protein and activity in the adult. We determined the potential of Plk1 to induce cell cycle progression and division in cultured rat cardiac myocytes. A persistent and progressive loss of Plk1 expression was observed during myocyte development that correlated with the withdrawal of adult rat cardiac myocytes from the cell cycle. Interestingly, when Plk1 was over-expressed in cardiac myocytes by adenovirus infection, it was not able to promote cell cycle progression, as determined by cell number and percent binucleation. We conclude that, in contrast to Cdc2/Cyclin B1 over-expression, the forced expression of Plk1 in adult cardiac myocytes is not sufficient to induce cell division and myocardial repair.
- 25 August 2009
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 4  (8) , e6752
Open AccessOver Expression of Plk1 Does Not Induce Cell Division in Rat Cardiac Myocytes In Vitro
Mammalian cardiac myocytes withdraw from the cell cycle during post-natal development, resulting in a non-proliferating, fully differentiated adult phenotype that is unable to repair damage to the myocardium, such as occurs following a myocardial infarction. We and others previously have shown that forced expression of certain cell cycle molecules in adult cardiac myocytes can promote cell cycle progression and division in these cells. The mitotic serine/threonine kinase, Polo-like kinase-1 (Plk1), is known to phosphorylate and activate a number of mitotic targets, including Cdc2/Cyclin B1, and to promote cell division. The mammalian Plk family are all differentially regulated during the development of rat cardiac myocytes, with Plk1 showing the most dramatic decrease in both mRNA, protein and activity in the adult. We determined the potential of Plk1 to induce cell cycle progression and division in cultured rat cardiac myocytes. A persistent and progressive loss of Plk1 expression was observed during myocyte development that correlated with the withdrawal of adult rat cardiac myocytes from the cell cycle. Interestingly, when Plk1 was over-expressed in cardiac myocytes by adenovirus infection, it was not able to promote cell cycle progression, as determined by cell number and percent binucleation. We conclude that, in contrast to Cdc2/Cyclin B1 over-expression, the forced expression of Plk1 in adult cardiac myocytes is not sufficient to induce cell division and myocardial repair.
- 13 August 2009
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 378  (1-2) , 201-210
Effect of acyl chain length on transfection efficiency and toxicity of polyethylenimine
- 13 August 2009
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 378  (1-2) , 201-210
Effect of acyl chain length on transfection efficiency and toxicity of polyethylenimine
- 5 March 2009
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 300  (1-2) , 71-76
Lys-gamma3-MSH: A global regulator of hormone sensitive lipase activity?
- 5 March 2009
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 300  (1-2) , 71-76
Lys-gamma3-MSH: A global regulator of hormone sensitive lipase activity?
- 1 April 2008
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 8  (2) , 193-201
Reprogramming the cell cycle machinery to treat cardiovascular disease
- 1 April 2008
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 8  (2) , 193-201
Reprogramming the cell cycle machinery to treat cardiovascular disease
- Open Access
- 1 May 2007
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 59  (5) , 609-628
The use of proteomics to identify novel therapeutic targets for the treatment of disease
The completion of the Human Genome Project has revealed a multitude of potential avenues for the identification of therapeutic targets. Extensive sequence information enables the identification of novel genes but does not facilitate a thorough understanding of how changes in gene expression control the molecular mechanisms underlying the development and regulation of a cell or the progression of disease. Proteomics encompasses the study of proteins expressed by a population of cells, and evaluates changes in protein expression, post-translational modifications, protein interactions, protein structure and splice variants, all of which are imperative for a complete understanding of protein function within the cell. From the outset, proteomics has been used to compare the protein profiles of cells in healthy and diseased states and as such can be used to identify proteins associated with disease development and progression. These candidate proteins might provide novel targets for new therapeutic agents or aid the development of assays for disease biomarkers. This review provides an overview of the current proteomic techniques available and focuses on their application in the search for novel therapeutic targets for the treatment of disease.
- 1 May 2007
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 59  (5) , 609-628
Open AccessThe use of proteomics to identify novel therapeutic targets for the treatment of disease
The completion of the Human Genome Project has revealed a multitude of potential avenues for the identification of therapeutic targets. Extensive sequence information enables the identification of novel genes but does not facilitate a thorough understanding of how changes in gene expression control the molecular mechanisms underlying the development and regulation of a cell or the progression of disease. Proteomics encompasses the study of proteins expressed by a population of cells, and evaluates changes in protein expression, post-translational modifications, protein interactions, protein structure and splice variants, all of which are imperative for a complete understanding of protein function within the cell. From the outset, proteomics has been used to compare the protein profiles of cells in healthy and diseased states and as such can be used to identify proteins associated with disease development and progression. These candidate proteins might provide novel targets for new therapeutic agents or aid the development of assays for disease biomarkers. This review provides an overview of the current proteomic techniques available and focuses on their application in the search for novel therapeutic targets for the treatment of disease.